giotrif 30mg comprimido recubierto
boehringer ingelheim peru s.a.c. - droguerÍa - dimaleato de afatinib; - comprimido recubierto - por comprimido - - afatinib
giotrif 40mg comprimido
boehringer ingelheim peru s.a.c. - droguerÍa - dimaleato de afatinib; - comprimido - por comprimido - - afatinib
giotrif 50 mg comprimido recubierto
boehringer ingelheim peru s.a.c. - droguerÍa - dimaleato de afatinib; - comprimido recubierto - por comprimido - - afatinib
giotrif 20 mg comprimidos recubiertos
drovital casa de representacion c.a. - afatinib - comprimidos recubiertos - 20 mg
giotrif 30 mg comprimidos recubiertos
drovital casa de representacion c.a. - afatinib - comprimidos recubiertos - 30 mg
giotrif 40 mg comprimidos recubiertos
drovital casa de representacion c.a. - afatinib - comprimidos recubiertos - 40 mg
giotrif 50 mg comprimidos recubiertos
boehringer ingelheim, c.a. - afatinib - comprimidos recubiertos - 50 mg
axitinib neoethicals 1 mg tabletas recubiertas
neoethicals - tabletas recubiertas - 1 mg
axitinib neoethicals 5 mg tabletas recubiertas
neoethicals - tabletas recubiertas - 5 mg
lorviqua
pfizer europe ma eeig - lorlatinib - carcinoma, pulmón no microcítico - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.